CH Emile Roux

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• COPD1 trial
• Osteoarthritis1 trial
• Osteoporosis1 trial
• Parkinson disease1 trial
• Psoriasis1 trial
• Triple-negative breast cancer1 trial
• Ulcerative colitis1 trial

Status

• Completed4 trials
• Not yet recruiting2 trials
• Recruiting1 trial

Lead sponsor

• Bristol-Myers Squibb1 trial
• Centre Hospitalier Universitaire de Saint Etienne1 trial
• DIAMPARK1 trial
• Institut Claudius Regaud1 trial
• Pfizer1 trial
• and 2 more

Running trials

• Recruiting

  A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)

  NCT06701513· Bristol-Myers Squibb· Source

  Contact: CHARLINE GARCIA, Site 074

• Not yet recruiting

  Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING)

  NCT06401395· DIAMPARK· Source

  Contact: Jérémie DASSA

• Recruiting

  Study of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis

  NCT05571514· Centre Hospitalier Universitaire de Saint Etienne· Source

  Contact: Benjamin CASTAGNE, MD (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Osteoporosis1 recruiting
• Parkinson disease1 recruiting
• Psoriasis1 recruiting

Closed trials

• Completed

  Effectiveness of the ARTH-e Application for Exercise Adherence in People With Knee Osteoarthritis : RCT

  NCT06359171· University Hospital, Clermont-Ferrand· Source

• Completed

  Oxygen Therapy Remote Monitoring in COPD Patients.

  NCT05473780· Vivisol· Source

• Completed

  Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

  NCT04424303· Pfizer· Source

• Completed

  Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm

  NCT02266420· Institut Claudius Regaud· Source